Department of Applied Biomedical Science, Faculty of Health Sciences, University of Malta, Msida, Malta.
Coagulation Medicine Laboratory, Department of Pathology, Mater Dei Hospital, Msida, Malta.
Thromb Res. 2024 Oct;242:109120. doi: 10.1016/j.thromres.2024.109120. Epub 2024 Aug 19.
Individuals with kidney failure have a compromised haemostatic system making them susceptible to both thrombosis and bleeding.
Assessment of primary haemostasis in patients treated with either haemodialysis (HD) or haemodiafiltration (HDF) was performed through the measurement of several coagulation-based tests, both pre- and post-dialysis.
PATIENTS/METHODS: 41 renal failure patients and 40 controls were recruited. Platelet aggregometry, Factor XIII (FXIII), Fibrinogen, Von Willebrand Factor (VWF) and Soluble P-Selectin (sP-Sel) levels were measured.
Maximum platelet aggregation was diminished in renal patients irrespective of aspirin intake. Post-dialysis, platelet function was exacerbated. Pre-dialysis FXIII levels were similar to the healthy cohort and became elevated post-dialysis. This elevation could not be explained by the relative decrease of water by dialysis. Fibrinogen levels were already elevated pre-dialysis and further increased post-dialysis. This elevation was associated with the relative decrease of water by dialysis. VWF levels in males were similar to the healthy cohort and became elevated post-dialysis. This elevation was associated with dialysis-related water loss. VWF antigen and activity in female patients were already elevated pre-dialysis and further increased post-dialysis with the exception of VWF activity in HDF treated female patients. sP-Sel levels were lower than those of the healthy cohort and became similar to the healthy cohort post-dialysis. This elevation could not be explained by the relative decrease of water by dialysis.
Whilst platelet aggregometry was diminished, we noted elevated clotting factors such as fibrinogen, FXIII and VWF with no significant differences between HD and HDF-treated patients.
肾衰竭患者的止血系统受损,容易发生血栓形成和出血。
通过测量几种基于凝血的测试,评估接受血液透析(HD)或血液透析滤过(HDF)治疗的患者的主要止血情况,包括透析前和透析后。
患者/方法:招募了 41 例肾衰竭患者和 40 例对照。测量了血小板聚集、因子 XIII(FXIII)、纤维蛋白原、血管性血友病因子(VWF)和可溶性 P 选择素(sP-Sel)水平。
无论是否服用阿司匹林,肾衰竭患者的最大血小板聚集均减弱。透析后血小板功能恶化。透析前 FXIII 水平与健康组相似,透析后升高。这种升高不能用透析相对减少水分来解释。纤维蛋白原水平在透析前已升高,并在透析后进一步升高。这种升高与透析相对减少水分有关。男性的 VWF 水平与健康组相似,透析后升高。这种升高与透析相关的水分丢失有关。女性患者的 VWF 抗原和活性在透析前已经升高,并在透析后进一步升高,但 HDF 治疗的女性患者的 VWF 活性除外。sP-Sel 水平低于健康组,透析后与健康组相似。这种升高不能用透析相对减少水分来解释。
尽管血小板聚集减弱,但我们注意到纤维蛋白原、FXIII 和 VWF 等凝血因子升高,HD 和 HDF 治疗患者之间无显著差异。